Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:47:58.447Z.
Calculation as of: 2026-10-06T19:47:58.447Z.
Quote observation: 2026-10-06T19:44:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1773f2c5e671cf5ca9c154ebb177a5c9f9e5edbe4e379a4b832a158831e220bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$8.91M
PS Ratio
5.20
TTM Avg
39.64
3Y Avg
50.81
5Y Avg
50.81
Market Cap
$9.66M
PS Ratio
0.97
TTM Avg
3.60
3Y Avg
6.58
5Y Avg
46.05
Market Cap
$10.01M
PS Ratio
182.06
TTM Avg
604.36
3Y Avg
203.60
5Y Avg
133.69
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | $9.17M | N/A | N/A | N/A | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.00M | N/A | N/A | N/A | N/A |
| SeaStar Medical Holding Corporation (ICU)vs › | $8.91M | 5.20 | 39.64 | 50.81 | 50.81 |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.66M | 0.97 | 3.60 | 6.58 | 46.05 |
| Ainos, Inc. (AIMD)vs › | $9.65M | 709.38 | 337.84 | 351.63 | 923.89 |
| MetaVia Inc. (MTVA)vs › | $9.82M | N/A | N/A | N/A | N/A |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | N/A | 91.76 | 49.38 | 97.49 |
| Senti Biosciences, Inc. (SNTI)vs › | $10.01M | 182.06 | 604.36 | 203.60 | 133.69 |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.32M | 0.32 | 0.20 | 0.21 | 0.26 |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.03M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
